A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals

被引：4

作者：

Bays, Harold E. ^{[1
]}

机构：

[1] Louisville Metab & Atherosclerosis Res Ctr Inc, 3288 Illinois Ave, Louisville, KY 40213 USA

来源：

JOURNAL OF CLINICAL LIPIDOLOGY | 2016年 / 10卷 / 02期

关键词：

Low-density lipoprotein cholesterol; Guidelines; Lipid goals; Recommendations; Atherosclerotic cardiovascular disease risk; CORONARY-HEART-DISEASE; LOW-DENSITY-LIPOPROTEIN; PATIENT-CENTERED MANAGEMENT; ACUTE MYOCARDIAL-INFARCTION; EARLY STATIN TREATMENT; ADULT TREATMENT PANEL; CARDIOVASCULAR-DISEASE; CHOLESTEROL LEVELS; PRIMARY-PREVENTION; SECONDARY PREVENTION;

D O I：

10.1016/j.jacl.2015.11.006

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Having knowledge of worldwide areas of harmonization and consensus regarding lipid guidelines and recommendations may provide clinicians a more global perspective on lipid management. This review examines 8 international scientific/medical organizations that have issued lipid guidelines, recommendations, and position papers: the National Lipid Association (2014), National Institute for Health and Care Excellence (2014), International Atherosclerosis Society (2013), American College of Cardiology/American Heart Association (2013), Canadian Cardiovascular Society (2013), Japan Atherosclerosis Society (2012), European Society of Cardiology/European Atherosclerosis Society (2012), and Adult Treatment Panel III (2001/2004). Part 1 of this perspective focused on sentinel components of these lipid guidelines and recommendations as applied to the role of atherogenic lipoprotein cholesterol levels, primary lipid target of therapy, other primary and secondary lipid treatment targets, and assessment of atherosclerotic cardiovascular disease (ASCVD) risk. This part 2 examines goals of lipid-altering therapy. While lipid guidelines and recommendations may differ regarding ASCVD risk assessment and lipid treatment goals, lipid guidelines and recommendations generally agree on the need to reduce atherogenic lipoprotein cholesterol levels, with statins being the first-line treatment of choice. (C) 2016 National Lipid Association. All rights reserved.

引用

页码：240 / 264

页数：25

共 113 条

[1] Mutations and Polymorphisms in the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene in Cholesterol Metabolism and Disease [J].

Abifadel, Marianne ;

Rabes, Jean-Pierre ;

Devillers, Martine ;

Munnich, Arnold ;

Erlich, Daniele ;

Junien, Claudine ;

Varret, Mathilde ;

Boileau, Catherine .

HUMAN MUTATION, 2009, 30 (04) :520-529

[2] New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk A Comparison of the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines with the 2014 National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia [J].

Adhyaru, Bhavin B. ;

Jacobson, Terry A. .

CARDIOLOGY CLINICS, 2015, 33 (02) :181-+

[3] Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease - The LDL-apheresis atherosclerosis regression study (LAARS) [J].

Aengevaeren, WRM ;

Kroon, AA ;

Stalenhoef, AFH ;

Uijen, GJH ;

vanderWerf, T .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 28 (07) :1696-1704

[4] 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult [J].

Anderson, Todd J. ;

Gregoire, Jean ;

Hegele, Robert A. ;

Couture, Patrick ;

Mancini, G. B. John ;

McPherson, Ruth ;

Francis, Gordon A. ;

Poirier, Paul ;

Lau, David C. ;

Grover, Steven ;

Genest, Jacques, Jr. ;

Carpentier, Andre C. ;

Dufour, Robert ;

Gupta, Milan ;

Ward, Richard ;

Leiter, Lawrence A. ;

Lonn, Eva ;

Ng, Dominic S. ;

Pearson, Glen J. ;

Yates, Gillian M. ;

Stone, James A. ;

Ur, Ehud .

CANADIAN JOURNAL OF CARDIOLOGY, 2013, 29 (02) :151-167

[5]

[Anonymous], 2014, LIP MOD CARD RISK AS

[6] Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial [J].

Armitage, Jane ;

Bowman, Louise ;

Wallendszus, Karl ;

Bulbulia, Richard ;

Rahimi, Kazem ;

Haynes, Richard ;

Parish, Sarah ;

Peto, Richard ;

Collins, Rory ;

Meade, T. ;

Sleight, P. ;

Collins, R. ;

Armitage, J. ;

Bowman, L. ;

Parish, S. ;

Peto, R. ;

Barton, J. ;

Bray, C. ;

Wincott, E. ;

Dayanandan, R. ;

Clarke, R. ;

Graham, I. ;

Simpson, D. ;

Warlow, C. ;

Wilken, D. ;

Tobert, J. ;

Mushner, T. ;

Doll, R. ;

Wilhelmsen, L. ;

Fox, K. ;

Hill, C. ;

Sandercock, P. ;

Webster, J. ;

Henderson, J. ;

Nixon, A. ;

Lackie, S. ;

Thompson, J. ;

Brown, M. ;

Blackwood, S. ;

Morgan, M. ;

Rhoden, W. ;

Saeed, B. ;

Houghton, M. ;

Nicholson, A. ;

Simpson, C. ;

Hoburn, B. ;

Cooper, I. ;

Gallivan, A. ;

Pickerell, E. ;

Hancock, J. .

LANCET, 2010, 376 (9753) :1658-1669

[7] Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention - The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study [J].

Athyros, VG ;

Papageorgiou, AA ;

Mercouris, BR ;

Athyrou, VV ;

Symeonidis, AN ;

Basayannis, EO ;

Demitriadis, DS ;

Kontopoulos, AG .

CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (04) :220-228

[8] Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].

Baigent, C. ;

Blackwell, L. ;

Emberson, J. ;

Holland, L. E. ;

Reith, C. ;

Bhala, N. ;

Peto, R. ;

Barnes, E. H. ;

Keech, A. ;

Simes, J. ;

Collins, R. .

LANCET, 2010, 376 (9753) :1670-1681

[9] Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].

Baigent, C ;

Keech, A ;

Kearney, PM ;

Blackwell, L ;

Buck, G ;

Pollicino, C ;

Kirby, A ;

Sourjina, T ;

Peto, R ;

Collins, R ;

Simes, J .

LANCET, 2005, 366 (9493) :1267-1278

[10] The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial [J].

Baigent, Colin ;

Landray, Martin J. ;

Reith, Christina ;

Emberson, Jonathan ;

Wheeler, David C. ;

Tomson, Charles ;

Wanner, Christoph ;

Krane, Vera ;

Cass, Alan ;

Craig, Jonathan ;

Neal, Bruce ;

Jiang, Lixin ;

Hooi, Lai Seong ;

Levin, Adeera ;

Agodoa, Lawrence ;

Gaziano, Mike ;

Kasiske, Bertram ;

Walker, Robert ;

Massy, Ziad A. ;

Feldt-Rasmussen, Bo ;

Krairittichai, Udom ;

Ophascharoensuk, Vuddidhej ;

Fellstrom, Bengt ;

Holdaas, Hallvard ;

Tesar, Vladimir ;

Wiecek, Andrzej ;

Grobbee, Diederick ;

de Zeeuw, Dick ;

Gronhagen-Riska, Carola ;

Dasgupta, Tanaji ;

Lewis, David ;

Herrington, William ;

Mafham, Marion ;

Majoni, William ;

Wallendszus, Karl ;

Grimm, Richard ;

Pedersen, Terje ;

Tobert, Jonathan ;

Armitage, Jane ;

Baxter, Alex ;

Bray, Christopher ;

Chen, Yiping ;

Chen, Zhengming ;

Hill, Michael ;

Knott, Carol ;

Parish, Sarah ;

Simpson, David ;

Sleight, Peter ;

Young, Alan ;

Collins, Rory .

LANCET, 2011, 377 (9784) :2181-2192

← 1 2 3 4 5 6 7 8 9 10 →